1. Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer. J Clin 2021; 71: 209-249.
2.
Robert-Koch-Institut (2024) Magenkrebs (Magenkarzinom). Available from: https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Magenkrebs/magenkrebs_node.html.
3.
Lindblad A, Kaucher S, Jaehn P, et al. The incidence of intestinal gastric cancer among resettlers in Germany – do resettlers remain at an elevated risk in comparison to the general population? Int J Environ Res Public Health 2020; 17: 9215.
4.
Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018; 10: 239-248.
5.
Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol 2023; 20: 338-349.
6.
Wu SL, Zhang Y, Fu Y, Li J, Wang JS. Gastric cancer incidence, mortality and burden in adolescents and young adults: a time-trend analysis and comparison among China, South Korea, Japan and the USA. BMJ Open 2022; 12: e061038.
7.
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet 2020; 396: 635-648.
8.
Lin Y, Pan X, Zhao L, et al. Immune cell infiltration signatures identified molecular subtypes and underlying mechanisms in gastric cancer. NPJ Genom Med 2021; 6: 83.
9.
Garbers C, Hermanns H, Schaper F, et al. Plasticity and cross-talk of Interleukin 6-type cytokines. Cytokine Growth Factor Rev 2012; 23: 85-97.
10.
Garbers C, Scheller J. Interleukin-6 and interleukin-11: same same but different. Biol Chem 2013; 394: 1145-1161.
11.
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harbor Perspect Biol 2014; 6: a016295.
12.
Coulie PG, Cayphas S, Vink A, Uyttenhove C, Van Snick J. Interleukin-HP1-related hybridoma and plasmacytoma growth factors induced by lipopolysaccharide in vivo. Eur J Immunol 1987; 17: 1217-1220.
13.
Elias J, Zheng T, Einarsson O, et al. Epithelial interleukin-11. Regulation by cytokines, respiratory syncytial virus, and retinoic acid. J Biol Chem 1994; 269: 22261-22268.
14.
Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334: 297-314.
15.
Rodig SJ, Meraz MA, White MJ, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the jaks in cytokine-induced biologic responses. Cell 1998; 93: 373-383.
16.
Müllberg J, Schooltink H, Stoyan T, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993; 23: 473-480.
17.
Garbers C, Jänner N, Chalaris A, et al. Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem 2011;. 286: 14804-14811.
18.
Riethmueller S, Somasundaram P, Ehlers JC, et al. Proteolytic origin of the soluble human IL-6R in vivo and a decisive role of n-glycosylation. PLoS Biol 2017; 15: e2000080.
19.
Lokau J, Nitz R, Agthe M, et al. Proteolytic cleavage governs interleukin-11 trans-signaling. Cell Rep 2016; 14: 1761-1773.
20.
Koch L, Kespohl B, Agthe M, et al. Interleukin-11 (IL-11) receptor cleavage by the rhomboid protease RHBDL2 induces IL-11 trans-signaling. FASEB J 2021; 35: e21380.
21.
Lokau J, Garbers C. Biological functions and therapeutic opportunities of soluble cytokine receptors. Cytokine Growth Factor Rev 2020; 55: 94-108.
22.
Schumertl T, Lokau J, Rose-John S, Garbers C. Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease. Biochim Biophys Acta Mol Cell Res 2022; 1869: 119143.
23.
Lokau J, Kespohl B, Kirschke S, Garbers C. The role of proteolysis in interleukin-11 signaling. Biochem Biophys Acta Mol Cell Res 2022; 1869: 119135.
24.
Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989; 169: 333-338.
25.
Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov 2018; 17: 395-412.
26.
Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol 2015; 34: 75-82.
27.
Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J. Targeting IL-6 trans-signalling: past, present and future prospects. Nat Rev Immunol 2023; 23: 666-681.
28.
Zhang S, Chen B, Wang B, et al. Effect of induction therapy with olamkicept vs placebo on clinical response in patients with active ulcerative colitis: a randomized clinical trial. JAMA 2023; 329: 725-734.
29.
Schreiber S, Aden K, Bernardes JP, et al. Therapeutic IL-6 trans-signalling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology 2021; 160: 2354-2366.e11.
30.
Schulte DM, Waetzig GH, Schuett H, et al. Case report: arterial wall inflammation in atherosclerotic cardiovascular disease is reduced by olamkicept (sgp130Fc). Front Pharmacol 2022; 13: 758233.
31.
Steadman T, O’Reilly S. Elevated interleukin-11 in systemic sclerosis and role in disease pathogenesis. J Dermatol 2023; 50: 1255-1261.
32.
Schafer S, Viswanathan S, Widjaja AA, et al. IL11 is a crucial determinant of cardiovascular fibrosis. Nature 2017; 552: 110-115.
33.
Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759.
34.
Giraldez MD, Carneros D, Garbers C, Rose-John S, Bustos M. New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology. Nat Rev Gastroenterol Hepatol 2021; 18: 787-803.
35.
Jackson C, Judd L, Menheniott T, et al. Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression. J Pathol 2007; 213: 140-151.
36.
Ellmark P, Ingvarsson J, Carlsson A, Lundin BS, Wingren C, Borrebaeck CA. Identification of protein expression signatures associated with Helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays Mol Cell Proteomics 2006; 5: 1638-1646.
37.
Judd LM, Alderman BM, Howlett M, et al. Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterology 2004; 126: 196-207.
38.
Tebbutt N, Giraud A, Inglese M, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002; 8: 1089-1097.
39.
Jenkins BJ, Grail D, Nheu T, et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 2005; 11: 845-852.
40.
Ernst M, Najdovska M, Grail D, et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008; 118: 1727-1738.
41.
Balic JJ, Garbers C, Rose-John S, Yu L, Jenkins BJ. Interleukin-11-driven gastric tumourigenesis is independent of trans-signalling. Cytokine 2017; 92: 118-123.
42.
Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 2019; 47: W556-W560.
43.
Fischer M, Goldschmitt J, Peschel C, et al. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 1997; 15: 142-145.
44.
Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992; 149: 2021-2027.
45.
Lokau J, Göttert S, Arnold P, et al. The SNP rs4252548 (R112H) which is associated with reduced human height compromises the stability of IL-11. Biochim Biophys Acta 2017; 1865: 496-506.
46.
Agthe M, Garbers Y, Grötzinger J, Garbers C. Two N-linked glycans differentially control maturation, trafficking and proteolysis, but not activity of the IL-11 receptor. Cell Physiol Biochem 2018; 45: 2071-2085.
47.
Kespohl B, Hartig R, Garbers Y, Lokau J, Garbers C. Coding variants of the interleukin-11 receptor with reduced protein maturation show protease-dependent trans-signaling and transduce normal STAT3 signaling. Genes Dis Press 2022; 10: 373-376.
48.
Sukri A, Hanafiah A, Kosai NR. The roles of immune cells in gastric cancer: anti-cancer or pro-cancer? Cancers (Basel) 2022; 14: 3922.
49.
Balic JJ, Saad MI, Dawson R, et al. STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis. Gut 2022; 71: 1515-1531.
50.
Dawson RE, Deswaerte V, West AC, et al. STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis. Gut 2022; 71: 1515-1531.
51.
Buzzelli JN, O’Connor L, Scurr M, et al. Overexpression of IL-11 promotes premalignant gastric epithelial hyperplasia in isolation from germline gp130-JAK-STAT driver mutations. Am J Physiol Gastrointest Liver Physiol 2019; 316: G251-G262.
52.
Sabry D, Abdelaleem OO, Hefzy EM, et al. Interplay between helicobacter pylori infection, interleukin-11, and leukemia inhibitory factor in gastric cancer among Egyptian patients. J Interferon Cytokine Res 2018; 38: 517-525.
53.
Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 2011; 90: 484-494.
54.
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813: 878-888.
55.
Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 2014; 70: 11-20.
56.
McFarland-Mancini M, Funk H, Paluch A, et al. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol 2010; 184: 7219-7228.
